Best Stocks To Invest In 2014

We haven't yet entered into the "irrational exuberance" we saw back in the 1990s; for now, we fully expect the Santa Claus Rally and January Effect to push the markets higher, forecasts Richard Schmidt, editor of Stellar Stock Alert.

During the market in the late 1990s, we saw companies with little revenue, but lots of promise, making huge inroads on the market. Today, it's just the opposite.

The companies getting rewarded are the companies that are producing. Companies that don't produce don't get rewarded by today's market. That's very bullish.

Meanwhile, the overall rally in Chinese stocks is paying off, with more room to grow. iShares FTSE/Xinhua China (FXI), which corresponds to the FTSE China 25 index, showed great strength mid-month, with a 10% jump in a matter of days.

The move indicates our push toward Chinese stocks is paying off, as this sector continues to improve. The overall rally in Chinese stocks is paying off, with more room to grow. FXI is a buy.

Best Stocks To Invest In 2014: eBay Inc.(EBAY)

eBay Inc. provides online platforms, services, and tools to help individuals and merchants in online and mobile commerce and payments in the United States and internationally. Its Marketplaces segment operates ecommerce platform eBay.com; vertical shopping sites, such as StubHub, Fashion, Motors, and Half.com; and classifieds Websites, including Den Bl�Avis, BilBasen, Gumtree, Kijiji, LoQUo, Marktplaats.nl, mobile.de, Alamaula, Rent.com, eBay Anuncios, eBay Kleinanzeigen, and eBay Annunci, as well as provides advertising services. The company?s Payments segment offers payment and settlement services for consumers and merchants on and off eBay Websites and other merchant Websites. This segment operates PayPal, which enables individuals and businesses to send and receive payments online and through mobile devices; Bill Me Later that enables the United States merchants to offer, the United States consumers to obtain, credit at the point of sale for ecommerce and mobile tra nsactions; Zong, which allows users with mobile phones to purchase digital goods and have the transactions charged to their phone bill; and BillSAFE that enables customers pay for purchases upon receipt of an invoice. Its GSI segment offers an ecommerce services suite for enterprise clients that operate in general merchandise categories, including apparel, sporting goods, toys and baby, health and beauty, and home; and marketing services comprising full-service digital agency, enterprise email marketing, mobile advertising, affiliate marketing, advertisement retargeting, and in-depth analytics services. The company also offers X.commerce platform that provides software developers access to the company?s applications programming interfaces to develop functionality for various merchants; and Magento Connect, which allows developers to market and sell add-on functionality and solutions to merchants that use a Magento storefront. eBay Inc. was founded in 1995 and is headquarter ed in San Jose, California.

Advisors' Opinion:

• [By Matt Jarzemsky]

  “That nearly every tech IPO associated with trends sucha s the cloud and social media has risen so much suggests investors are chasing all of the companies,” Janus says. Just the dot-com era’s failures far outnumber Amazon.com Inc.(AMZN), Ebay Inc.(EBAY) and other success stories, “there is a high probaility that many, though not all, of these companies will stumble.”

• [By Steve Heller]

  Commerce
  Thanks to the rise of smartphones and tablets, John Donahoe, the CEO of eBay (NASDAQ: EBAY  ) , believes another 2 billion Internet users will come online in the next three to five years. He also believes that the nature of commerce will change more in the coming three years than it has over the past 15. As a global commerce platform equipped with a thriving PayPal business, eBay expects that it will enable more than $300 billion of global commerce by 2015. For those keeping track at home, this represents an increase of $125 billion from 2012 levels. The smartphone has completely reshaped the world of commerce, and eBay is in excellent position to benefit from the fact that more users will begin shopping on the world's marketplace.

Best Stocks To Invest In 2014: IAC/InterActiveCorp (IACI)

IAC/InterActiveCorp engages in the Internet business in the United States and internationally. The company�s Search segment develops, markets, and distributes various downloadable toolbars; provides search, reference, and content services through its destination search and other Websites, including Ask.com and Dictionary.com; and aggregates and integrates local advertising and content for distribution to publishers on Web and mobile platforms, as well as markets and distributes mobile applications through which it provides search and additional services. Its Match segment offers subscription-based and advertiser-supported online personals services through its Websites comprising Match.com, Chemistry.com, OurTime.com, BlackPeopleMeet.com, and OkCupid.com, as well as through mobile applications and Meetic-branded Websites. The company�s ServiceMagic segment offers Market Match service that matches consumers with service professionals; Exact Match service, which enables con sumers to review service professional profiles and select the service professional that meets their specific needs; and 1800Contractor.com, an online directory of service professionals. This segment also offers Website design and hosting services. Its Media and Other segment operates CollegeHumor.com, an online entertainment Website that targets young males; Vimeo, a Website on which users can upload, share, and view video; and Pronto.com, a comparison search engine. This segment also engages in the creation of video content for various distribution platforms; and operates as an Internet retailer of footwear and related apparel and accessories, as well as focuses on multimedia business. The company was formerly known as InterActiveCorp and changed its name to IAC/InterActiveCorp in July 2004. IAC/InterActiveCorp was founded in 1986 and is headquartered in New York, New York.

Advisors' Opinion:

• [By Jayson Derrick]

  InterActiveCorp (NASDAQ: IACI) announced that its CEO is stepping down from his current position to become chairman of a new operating unit. Investors cheered the management shakeup which is potentially hinting at a spinoff. Shares hit new 52 week highs of $70.44 before closing at $68.49, up 13.98 percent.

• [By Mani]

  IAC InterActive Corp. (NASDAQ:IACI) should see improved margins and revenue from its Match business as subscriber growth could be boosted by favorable secular trends and new monetizing opportunities.

Best Long Term Stocks To Own For 2014: MiMedx Group Inc (MDXG)

MiMedx Group, Inc. (MiMedx), incorporated on February 28, 2008, is an integrated developer, manufacturer and marketer of regenerative biomaterial products processed from human amniotic membrane. The Company�� biomaterial platform technologies include the device technologies HydroFix and CollaFix, and tissue technologies, AmnioFix and EpiFix. Its tissue technologies are processed from human amniotic membrane that is derived from the donated placentas. Through the Company�� donor program, mothers delivering full-term caesarian births can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. MiMedx processes the human amniotic membrane utilizing its Purion Process to produce a manipulated implant for homologous use. MiMedx is the supplier of amniotic tissue, having supplied over 100,000 implants to distributors and other equipment manufacturers (OEMs) for application in the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental sectors of healthcare.

The Company has three platform technologies. Its largest addressable market is in chronic wound care consisting of diabetic, venous and pressure ulcers. On January 5, 2011, the Company acquired all of the outstanding equity interests in Surgical Biologics, LLC. Located in Kennesaw, Georgia, Surgical Biologics develops allografts and other products processed from human amniotic membrane that can be used for a range of medical applications, including ocular surface repair, gum repair, wound care, nerve and tendon repair, spine repair, burn treatment, and many other types of procedures that require the repair of a patient�� integumental (native) tissue. Surgical Biologics has developed a specialized process for the processing of amniotic membrane to produce a manipulated allograft for homologous use.

AmnioFix and EpiFix

MiMedx is the supplier of allografts processed from amniotic tissue, having supplied over 70,000 allografts to date for application in the Ophthalm! ic, Orthopedic, Dental, Spinal and Wound Care segments of healthcare. Its amnion products, AmnioFix and EpiFix, are processed from human tissue. The AmnioFix and EpiFix allografts can be used for a range of procedures, including ocular surface repair, gingival recession repair, wound care, burns, and many other types of procedures for the repair of a patient�� integumental (native) tissue. Its AmnioFix technology also is used as a graft to reduce the amount of scar tissue formation, provide a local anti-inflammatory and help with the soft tissue healing of the area. EpiFix offers a range of wound healing and wound care options. Much of the clinical usage of EpiFix has been for wound care patients suffering from diabetic ulcers, pressure ulcers, vein circulation ulcers, or artery circulation ulcers.

CollaFix

The Company�� CollaFix technology combines a means of creating fibers from soluble collagen and a specialized cross-linking process. MiMedx utilizes two separate cross-linking technologies for various applications. Initial laboratory and animal testing shows that the cross-linked collagen fibers produce a biocompatible, and durable construct that can be transformed into surgical meshes intended to treat a number of orthopedic soft-tissue trauma and disease disorders.

HydroFix

The Company licenses rights to a polyvinyl alcohol (PVA) polymer, which is a water-based biomaterial that can be manufactured with a range of mechanical properties, including those that appear to mimic closely the mechanical and physical properties of natural, healthy human tissue. This hydrogel has been used in other orthopedic and general surgery device applications, and it has demonstrated biocompatibility and durability inside the human body. It has a similar version of the product for the European market called HydroFix Spine Shield. The device is classified as a post-surgical adhesion inhibiting barrier and is used in specific spine surgeries. In December the original! HydroFix! Spine Shield (for Anterior use Class IIb in Europe) was renamed to be HydroFix Anterior Shield.

The Company competes with W.L. Gore & Associates, Inc. and Stryker.

Advisors' Opinion:

• [By Teresa Rivas]

  The Securities and Exchange Commission charged Arrowood and Petit, CEO of MiMex Group (MDXG), in January of last year. The SEC alleges that Arrowood received non-public information about the potential sale of Matria Healthcare (a publicly traded company that merged with Inverness Medical Innovations in 2008) from Petit, who was CEO of the firm at that time.

• [By Sean Williams]

  What: Shares of MiMedx Group (NASDAQ: MDXG  ) , a manufacturer of patented regenerative biomaterial products (in essence, products designed to treat inflammation and help wounds heal), were eviscerated, falling as much as 70% at one point before recovering half of its losses after it announced the receipt of an untitled letter from the Food and Drug Administration alleging it does not possess the proper licensing to manufacture certain products.

• [By Rich Smith]

  MiMedx Group (NASDAQ: MDXG  ) ,�announced�Monday that results from a randomized controlled trial for its EpiFix wound-care allograft have been published in the International Wound Journal.�
  
  The clinical trial included patients with diabetic foot ulcers of at least four weeks' duration without infection, having adequate blood supply. Patients were broken into two groups, one receiving standard care alone, the other standard care plus EpiFix. After four and six weeks of treatment, the overall healing rate of patients treated with EpiFix was 77% and 92%, respectively, whereas standard care healed 0% and 8% of the wounds, respectively. The rate of healing with EpiFix exceeded that of standard treatment as well.
  
  According to the World Health Organization, diabetes will affect 366 million people worldwide -- up from 171 million in 2000.�Approximately 25% of diabetics will develop a chronic non-healing ulcer over their lifetime.�Diabetic foot ulcers�occur in 15% of all patients with diabetes and precede 84% of all lower leg amputations.
  
  EpiFix makes use of dehydrated human amniotic membrane to heal these ulcers. At room�temperature, EpiFix can have a shelf life of five years and retains the properties of the natural membrane.�Although there are similar, competing products on the market, the superior performance of�EpiFix compared with rival products (not yet proven by published studies) could help to make the company a market leader in the treatment of diabetic foot ulcers.

Best Stocks To Invest In 2014: Micropac Industries Inc (MPAD)

Micropac Industries, Inc. (Micropac), incorporated on March 3, 1969, manufactures and distributes various types of hybrid microelectronic circuits, solid state relays, power operational amplifiers, and optoelectronic components and assemblies. Micropac�� products are used as components in a range of military, space and industrial systems, including aircraft instrumentation and navigation systems, power supplies, electronic controls, computers, medical devices, and high-temperature (200o degree Celsius) products. The Company�� products are either custom (being application-specific circuits designed and manufactured to meet the particular requirements of a single customer) or standard components. During the fiscal year ended December 31, 2011 (fiscal 2011), its custom-designed components accounted for approximately 34% of its revenue and standard components accounted for approximately 66% of its revenue.

Micropac occupies approximately 36,000 square feet of manufacturing, engineering and office space in Garland, Texas. The Company owns 31,200 square feet of that space and leases an additional 4,800 square feet. It also sub-contracts some manufacturing to Inmobiliaria San Jose De Ciuddad Juarez S.A. DE C.V, a maquila contract manufacturer in Juarez, Mexico.

Micropac provides microelectronic and optoelectronic components and assemblies along with contract electronic manufacturing services, and offers a range of products sold to the industrial, medical, military, aerospace and space markets. The Microcircuits product line includes custom microcircuits, solid state relays, power operational amplifiers, and regulators. During fiscal 2011, microcircuits product line accounted for 51% of its revenue and the optoelectronics product line accounted for 62% of its business respectively. The Company�� core technology is the packaging and interconnects of miniature electronic components, utilizing thick film and thin film substrates, forming microelectronics circuits. Other technologi! es include light emitting and light sensitive materials and products, including light emitting diodes and silicon phototransistors used in its optoelectronic components, and assemblies.

The Company�� basic products and technologies include custom design hybrid microelectronic circuits, solid state relays and power controllers, custom optoelectronic assemblies and components, optocouplers, light-emitting diodes, Hall-Effect devices, displays, power operational amplifiers, fiber optic components and assemblies, and high temperature (200o degree Celsius) products. Micropac�� products are primarily sold to original equipment manufacturers (OEM��) who serve major markets, which includes military/aerospace, such as aircraft instrumentation, guidance and navigations systems, control circuitry, power supplies and laser positioning; space, which include control circuitry, power monitoring and sensing, and industrial, which includes power control equipment and robotics.

The Company�� products are marketed throughout the United States and in Western Europe. During fiscal 2011, approximately 21% of the Company�� revenue was from international customers. The Company�� major customers include contractors to the United States Government. During fiscal 2010, sales to these customers for the Department of Defense (DOD) and National Aeronautics and Space Administration (NASA) contracts accounted for approximately 62% of its revenues. The Company�� customers are Lockheed Martin, Northrop Grumman, Boeing, Rockwell Int��, and NASA.

The Company compete with Teledyne Industries, Inc., MS Kennedy, Honeywell, Avago and International Rectifier.

Advisors' Opinion:

• [By Geoff Gannon] % of NCAV, has similar (slightly better) z- and f-scores, a FCF margin of 6%, but has ROA of 28%.
  
  ADDvantage (AEY) sells at 95% of NCAV, has similar (in the ballpark) scores and FCF and ROA of 23%.

  The slightly better businesses are currently more expensive in terms of price/NCAV. They have less asset-based downside protection, but they are better businesses.

  How do you quantify and qualify what is cheap enough? To me, there's a big difference in relative cheapness in a company selling at 74% of NCAV versus one selling at 95%. I'm wondering if I'm putting too much weight on this cheapness measurement instead of acknowledging that any decent business selling at less than NCAV is cheap enough. Yet, one has to have some quantifiable idea of when something is not cheap enough anymore.

  Can you help me put this into a unified framework?

  Dan

  There�� a great post over at Oddball Stocks called: �� Stock is a Business�� Read it. Then go over to Richard Beddard�� Interactive Investor Blog. Bookmark that blog. Read it religiously. He looks at Ben Graham type stocks in the U.K. And he looks at them not just as stocks but as pieces of a business.

  Here�� what Richard said in a post called ��iving Up on Mastery of the Universe��

  I need to know:

  1. Whether the managers have made good decisions in the past, and whether their incentives work in the interests of the owners, because those kind of managers often add value to a company.

  2. The products a company sells will still be in demand for years to come, because if they��e not then the past, which we know, does not tell us anything about the future, which we don��.

  3. A company is financially strong enough to withstand the kinds of shocks companies typically experience bearing in mind some are more sensitive to events than others.

  4. How to judge whether the share price undervalues the company, bearing in mind the preceding three factors.

• [By Geoff Gannon] strong>ADDvantage Technologies (AEY)

  路 Solitron Devices (SODI)

  路 OPT-Sciences (OPST)

  Micropac

  Micropac is 76% owned by Heinz-Werner Hempel. He�� a German businessman. You can see the German company he founded here. He�� had control of Micropac for a long-time. I don�� have an exact number in front of me. But I would guess it�� been something like 25 years.

  ADDvantage

  ADDvantage Technologies is controlled by the Chymiak brothers. See the company�� April 4 press release explaining their decision to turn over the CEO position to an outsider. Regardless, the Chymiaks still control 47% of the company. Ken Chymiak is now chairman. And David Chymiak is still a director and now the company�� chief technology officer. Clearly, it�� still their company.

  By the way, the name ADDvantage Technologies has nothing to do with the Chymiaks. Today�� AEY really traces its roots to a private company called Tulsat. The Chymiak brothers acquired that company about 27 years ago. So, effectively, when you buy shares of AEY you are buying into a 27-year-old family-controlled company.

  That�� pretty typical in the world of net-nets.

  Solitron

  Solitron Devices is 29% owned by Shevach Saraf. He has been the CEO for 20 years. The post-bankruptcy Solitron has never known another CEO. Before the bankruptcy, Solitron was a much bigger, much different company. So even though we are not talking about the founder here ��and even though 70% of the company�� shares are not held by the CEO ��we��e still talking about a company where one person has a lot of control. Solitron only has three directors. Saraf is the chairman, CEO, president, CFO and treasurer. Neither of the other two directors joined the board within the last 15 years. So, we aren�� talking about a lot of tumult at the top.

  In fact, profitable net-nets seem to be especially common candidates for abandoning the responsibilities of a public comp

Best Stocks To Invest In 2014: Encana Corporation(ECA)

Encana Corporation and its subsidiaries engage in the exploration for, development, production, and marketing of natural gas, oil, and natural gas liquids. The company owns interests in resource plays that primarily include the Greater Sierra, Cutbank Ridge, Bighorn, and Coalbed Methane resource plays located in British Columbia and Alberta, as well as the Deep Panuke natural gas project offshore Nova Scotia in Canada. It also holds interests in resource plays comprising the Jonah in southwest Wyoming, Piceance in northwest Colorado, Haynesville in Louisiana, and Texas resource play, including east Texas and north Texas. The company serves primarily local distribution companies, industrials, energy marketing companies, and other producers. Encana Corporation was founded in 1971 and is headquartered in Calgary, Canada.

Advisors' Opinion:

• [By Arjun Sreekumar]

  Comparing CEO compensations
  Last year, McClendon received a base salary of $975,000 and a total compensation of $16.9 million. Meanwhile, chief executives at Encana (NYSE: ECA  ) and Southwestern Energy (NYSE: SWN  ) , two natural gas producers with very similar market capitalizations, had substantially smaller pay packages last year.

Best Stocks To Invest In 2014: Prosensa Holding NV (RNA)

Prosensa Holding N.V., formerly Prosensa Holding B.V., is a biotechnology company engaged in the discovery and development of ribonucleic acid-modulating (RNA)-modulating, therapeutics for the treatment of genetic disorders. The Company�� primary focus is on rare neuromuscular and neurodegenerative disorders with a large unmet medical need, including Duchenne muscular dystrophy, myotonic dystrophy and Huntington�� disease. The Company�� clinical portfolio of RNA-based product candidates is focused on the treatment of Duchenne muscular dystrophy (DMD). The Company�� platform technology allows the development of RNA-modulating therapeutics that either interferes with splicing (exon skipping, exon inclusion, or splice mutation correction), remove mutant RNA, or block RNA expression, for different indications.

DMD is a rare, severe muscle wasting disease that occurs in up to 1 in 3,500 male births. It is commonly diagnosed between the ages of three to five, when boys begin to show signs of impaired motor development. PRO044, the Company�� product candidate, addresses a separate sub-population of DMD patients. The Company developed PRO044 using its exon-skipping technology to generate a product candidate with the same mechanism of action that is used by drisapersen.

Advisors' Opinion:

• [By Keith Speights]

  Successful launch
  You couldn't even buy stock in Prosensa (NASDAQ: RNA  ) just a few weeks ago. The biotech launched its IPO on June 28. To say that launch has gone successfully is an understatement. Shares are now more than double the IPO price and climbed 41% this week.

• [By Sean Williams]

  Shares of Sarepta climbed to a 52-week high of $55.61 in September shortly after an experimental rival drug, drisapersen, developed by Prosensa (NASDAQ: RNA  ) and GlaxoSmithKline (NYSE: GSK  ) , missed its primary end point by a mile in late-stage trials. However, Sarepta also tanked just weeks later after the Food and Drug Administration decided against supporting an accelerated drug approval for eteplirsen; the agency would not make the connection that increased dystrophin production led to its remarkable trial results.�Also, given the recent failure of drisapersen in a phase 3 study, the FDA felt it pertinent that Sarepta engage in a broader study. Shares ultimately dipped as low as $12.12.�

• [By John Udovich]

  It should also be mentioned that earlier in the week, GlaxoSmithKline plc (NYSE: GSK) returned full rights of Duchenne muscular dystrophy drug drisapersen to their partner�Prosensa Holding NV (NASDAQ: RNA) and that news sent shares down 12.48% on�Monday. Moreover,�Prosensa Holding also sank some 70% last fall when Drisapersen failed a phase 3 trial by missing a primary endpoint measuring for how far patients could walk over the course of six minutes (the improvement�wasn't significantly better than the placebo).�However, Prosensa Holding also rose 24.37% yesterday after announcing�initial findings from further analyses from the aggregate data for drisapersen, with the CEO saying:

Best Stocks To Invest In 2014: Compass Diversified Holdings (CODI)

Compass Diversified Holdings is a public investment firm specializing in acquiring controlling stakes in small to middle market companies. The firm seeks to make middle market and buyout investments. It seeks to invest in industries such as manufacturing, distribution, consumer products, and business services. The firm prefers to invest in companies based in North America with a preferred transaction size between $60 million and $300 million in value, cash flows between $5 million and $40 million, with enterprise values between $50 million and $250 million, and a minimum EBITDA of $10 million. It seeks to acquire controlling ownership interests in its portfolio companies and can also make additional platform acquisitions. The firm makes investments through balance sheet. Compass Diversified Holdings was founded in 2005 and is based in Westport, Connecticut. Compass Diversified Holdings operates as a subsidiary of The Compass Group LLC.

Advisors' Opinion:

• [By Rick Munarriz]

  Compass Diversified Holdings (NYSE: CODI  ) owns several middle-market businesses. From printed circuit boards to gun safes -- from upholstered furniture to personal hydration products -- Compass lives up to the "Diversified" in its moniker.

• [By Rick Munarriz]

  I went out on a limb last week, and now it's time to see how that decision played out.

  I predicted that Clean Energy Fuels (NASDAQ: CLNE  ) would close higher on the week. The provider of natural gas fueling solutions for transportation has been posting narrowing losses, and Wall Street was eyeing a 35% surge in revenue. The company was a solid report. Revenue came in a little light, but bottom-line results improved nicely. Shares of Clean Energy Fuels moved slightly higher on the week. I was right. I predicted that the tech-heavy Nasdaq would outperform the Dow Jones Industrial Average. (DJINDICES: ^DJI  ) . This has been a tricky call lately, so how did it play out this time? Well, the market had a strong run this week, fueled be encouraging economic news. Secondary stocks led the way, with the Nasdaq soaring 1.7% on the week. The Dow managed to close just 1% higher. I was right. My final call was for Compass Diversified Holdings (NYSE: CODI  ) to beat Wall Street's quarterly profit target. The investor in several middle-market companies has been posting blowout quarterly results over the past year, and I was banking on seeing the trend continue. Analysts were looking for a profit of $0.36 a share during the quarter, but Compass Diversified failed to beat the prognosticators. I was wrong.

  Two out of three? I'll take it. That makes me eight of nine over the past three weeks.

• [By Rich Smith]

  Westport, Conn.-based Compass Diversified Holdings (NYSE: CODI  ) will soon have a new CFO.

  On Thursday, the diversified holding company of manufacturing, distribution, consumer products, and services businesses announced that current Chief Financial Officer James J. Bottiglieri intends to retire from the company on November 30, 2013. At that time, he will be replaced by newly promoted CFO Ryan J. Faulkingham (although Bottiglieri will remain on the Board of Directors).

Best Stocks To Invest In 2014: Retail Opportunity Investments Corp.(ROIC)

Retail Opportunity Investments Corp., a real estate investment trust (REIT), engages in the acquisition, ownership, and management of necessity-based community and neighborhood shopping centers in the eastern and western regions of the United States. As of December 31, 2011, its portfolio consisted of 30 owned retail properties totaling approximately 3.2 million square feet of gross leasable area. The company has elected to be taxed as a REIT, for U.S. federal income tax purposes. The company is based in White Plains, New York.

Advisors' Opinion:

• [By Brian Stoffel]

  Retail Opportunity Investment Corp. (NASDAQ: ROIC  )
  Fool analyst Michael Olsen tends to focus on overlooked companies that offer up deals based on the difference between a stock's price and its intrinsic value. His recent pick of ROIC stock is right down his alley.

Best Stocks To Invest In 2014: Renishaw PLC (RSW)

Renishaw plc is a metrology company. The Company is engaged in the design, manufacture and sale of advanced precision metrology and inspection equipment together with products for the healthcare sector, including Raman spectroscopy systems, dental systems, molecular diagnostic equipment and neurosurgical products. The Company operates in two segments: metrology and healthcare products. The Company�� metrology segment product include Machine Tool Probe Systems, Co-ordinate Measuring Machine (CMM) products, large scale metrology, fixtures, materials research, styli for probe systems, performance testing products, gauging and position encoders. Its healthcare products include Dental Scanners, Raman Microscopes, Dental CAD Software, Neurosurgical robot, Structural and Chemical Analyser, In situ monitors and Neurosurgical Implantables. Advisors' Opinion:

• [By Inyoung Hwang]

  Renishaw Plc (RSW) tumbled 5.7 percent to 1,580 pence, its lowest price since Aug. 7. The maker of precision tools said revenue for the quarter ended in September fell to 79 million pounds from 95.9 million pounds in the year-ago period.

Best Stocks To Invest In 2014: LCA-Vision Inc.(LCAV)

LCA-Vision Inc. provides fixed-site laser vision correction services through its LasikPlus vision centers. Its vision centers offer laser vision correction services for correcting nearsightedness, farsightedness, and astigmatism. As of December 31, 2011, the company operated 53 LasikPlus fixed-site laser vision correction centers located in metropolitan markets in the United States. LCA-Vision Inc. was founded in 1985 and is headquartered in Cincinnati, Ohio.

Advisors' Opinion:

• [By Lisa Levin]

  Medical Practitioners: This industry jumped 2.82% by 10:15 am. The top performer in this industry was LCA-Vision (NASDAQ: LCAV), which rose 2.9%. LCA-Vision's trailing-twelve-month revenue is $91.12 million.